4613347709

sufncient to elear mfection. We also analyzed the cross-neutralization ability of the antibodies elicited by the mutants to neutralize WT VSV. We found that even though the point mutations found in the glycoprotein of Gć and Gór mutants lie in close proximity to the dominant neutralizing B-cell epitope (Vandepol et al., 1986), cross-neutralization occurred for all mutants. These results suggest that all VSV mutants should be safe oncolytic agents because they are rapidly cleared invivo, however this will likely limit the treatment efficacy

window.